Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

Phase 2

Completed

Conditions: Cancer
Breast Cancer

Interventions: Biological: Nivolumab
Drug: Anastrozole
Drug: Palbociclib

First Posted Date: 2019-09-03

Last Posted Date: 2022-08-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 23

Registration Number: NCT04075604

Locations: 🇺🇸
The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

and more 28 locations

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Phase 1

Completed

Conditions: Healthy Participants
Idiopathic Pulmonary Fibrosis (IPF)

Interventions: Diagnostic Test: 18F-BMS-986327

First Posted Date: 2019-08-28

Last Posted Date: 2023-03-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 14

Registration Number: NCT04069143

Locations: 🇺🇸
Local Institution - 0001, New Haven, Connecticut, United States

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

Phase 1

Completed

Conditions: Lupus

Interventions: Drug: BMS-986165-01
Drug: BMS-986165 Tablet
Drug: Famotidine

First Posted Date: 2019-08-22

Last Posted Date: 2021-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 33

Registration Number: NCT04065932

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: Ritonavir

First Posted Date: 2019-08-13

Last Posted Date: 2020-06-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT04055506

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Study of Nivolumab in Patients With Head and Neck Cancer.

Active, not recruiting

Conditions: Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck

Interventions: Biological: Nivolumab

First Posted Date: 2019-08-08

Last Posted Date: 2023-03-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 502

Registration Number: NCT04050761

Locations: 🇫🇷
Local Institution - 0001, Paris, France

A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2019-08-05

Last Posted Date: 2021-08-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 260

Registration Number: NCT04045639

Locations: 🇬🇧
Local Institution, Worcester, United Kingdom

A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

Completed

Conditions: Advanced or Metastatic Renal Cell Carcinoma

First Posted Date: 2019-08-02

Last Posted Date: 2025-02-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 286

Registration Number: NCT04043975

Locations: 🇯🇵
Local Institution - 0001, Tokyo, Japan

Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Mycophenolate Mofetil

First Posted Date: 2019-07-31

Last Posted Date: 2020-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT04039373

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Phase 3

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Nivolumab
Drug: Sorafenib
Drug: lenvatinib
Drug: Ipilimumab

First Posted Date: 2019-07-31

Last Posted Date: 2024-05-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 732

Registration Number: NCT04039607

Locations: 🇺🇸
Local Institution - 0295, Newark, New Jersey, United States
🇧🇷
Local Institution - 0061, Salvador, Bahia, Brazil
🇦🇺
Local Institution - 0038, Liverpool, New South Wales, Australia

and more 202 locations

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

Phase 3

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: BMS-986165

First Posted Date: 2019-07-29

Last Posted Date: 2023-09-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1452

Registration Number: NCT04036435

Locations: 🇺🇸
First OC Dermatology & Belle-Aimee Skincare Clinic Fountain Valley, Fountain Valley, California, United States
🇺🇸
Local Institution - 0007, Miami Lakes, Florida, United States
🇺🇸
Radiant Research - Anderson, Anderson, South Carolina, United States

and more 267 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy